Research/art/teacher profile of a person

Name and surname:	Mgr. Veronika Vyletelová, PhD.
Document type:	Research/art/teacher profile of a person
The name of the university:	Comenius University Bratislava
The seat of the university:	Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname

Vyletelová

I.2 - Name

Veronika

I.3 - Degrees

Mgr. PhD.

I.4 - Year of birth

1995

I.5 - Name of the workplace

Department of Cellular and Molecular Biology of Drugs

I.6 - Address of the workplace

Kalinčiakova 8, 832 32 Bratislava

I.7 - Position

assistent professor

I.8 - E-mail address

vyletelova6@uniba.sk

I.10 - Name of the study field in which a person works at the university

Pharmacy

I.11 - ORCID iD

https://orcid.org/0009-0000-5229-6550

II. - Higher education and further qualification growth

II.1 - First degree of higher education

II.2 - Second degree of higher education

II.a - Name of the university or institution

Faculty of Pharmacy, Comenius University in Bratislava

II.b - Year

2020

II.c - Study field and programme

Pharmacy

II.3 - Third degree of higher education

II.a - Name of the university or institution

Faculty of Pharmacy, Comenius University in Bratislava

II.b - Year

2024

II.c - Study field and programme

Pharmacology

II.4 - Associate professor

II.5 - Professor

II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position	III.b - Institution	III.c - Duration
assistant professor	Faculty of Pharmacy, Comenius University in Bratislava	2024

IV. - Development of pedagogical, professional, language, digital and other skills

IV.a - Activity description, course name, other	IV.b - Name of the institution	IV.c - Year
Cardioscope/Atheronet training school: ,,Omics for precision Medicine in ASCVD"	COST Action AtheroNET, CA21125	2024

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes

V.1.a - Name of the profile course	V.1.b - Study programme	V.1.c - Degree	V.1.d - Field of study
Applied biochemistry	Pharmacy	1. and 2.	Pharmacy
Biochemistry	Pharmacy	1. and 2.	Pharmacy

V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year

V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year

V.4 - Overview of supervised final theses

V.4.1 - Number of currently supervised theses

V.4.2 - Number of defended theses

V.4.b - Diploma (second degree)

4 - consultant

V.5 - Overview of other courses taught in the current academic year according to study programmes

V.5.a - Name of the course	V.5.b - Study programme	V.5.c - Degree	V.5.d - Field of study
Advanced cell-biology methods	Pharmacy	1. and 2.	Pharmacy

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations

VI.1.1 - Number of the research/artistic/other outputs

VI.1.a - Overall

11

VI.1.b - Over the last six years

11

VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases

VI.1.a - Overall

4

VI.1.b - Over the last six years

4

VI.1.3 - Number of citations corresponding to the research/artistic/other outputs

VI.1.a - Overall

16

VI.1.b - Over the last six years

16

VI.1.4 - Number of citations registered in the Web of Science or Scopus databases

VI.1.a - Overall

13

VI.1.b - Over the last six years

13

VI.1.5 - Number of invited lectures at the international, national level

VI.1.a - Overall

1

VI.1.b - Over the last six years

1

VI.2 - The most significant research/artistic/other outputs

1

Vyletelová V, Nováková M, Pašková Ľ. Alterations of HDL's to piHDL's Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. Pharmaceuticals (Basel). 2022 Oct 18;15(10):1278. doi: 10.3390/ph15101278. PMID: 36297390; PMCID: PMC9611871.

2

Nováková M, Vyletelová V, Hlubinová B, Kiňová Sepová H, Pašková Ľ. Impact of culture medium on the interpretation of qRT-PCR data in HepG2 incubated with lactobacilli. Lett Appl Microbiol. 2024 Jun 3;77(6):ovae050. doi: 10.1093/lambio/ovae050. PMID: 38806242.

3

Chrastina M, Poništ S, Tóth J, Czigle S, Pašková Ľ, Vyletelová V, Švík K, Bauerová K. Combination Therapy of Carnosic Acid and Methotrexate Effectively Suppressed the Inflammatory Markers and Oxidative Stress in Experimental Arthritis. Molecules. 2022 Oct 21;27(20):7115. doi: 10.3390/molecules27207115. PMID: 36296709; PMCID: PMC9612293.

4

Pružinská K, Chrastina M, Khademnematolahi S, Vyletelová V, Gajdošová L, Pastvová L, Dráfi F, Poništ S, Pašková Ľ, Kucharská J, Sumbalová Z, Muchová J, Martiniaková S, Bauerová K. Astaxanthin, Compared to Other Carotenoids, Increases the Efficacy of Methotrexate in Rat Adjuvant Arthritis. Int J Mol Sci. 2024 Aug 9;25(16):8710. doi: 10.3390/ijms25168710. PMID: 39201397; PMCID: PMC11354740.

VI.3 - The most significant research/artistic/other outputs over the last six years

1

Vyletelová V, Nováková M, Pašková Ľ. Alterations of HDL's to piHDL's Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. Pharmaceuticals (Basel). 2022 Oct 18;15(10):1278. doi: 10.3390/ph15101278. PMID: 36297390; PMCID: PMC9611871.

2

Nováková M, Vyletelová V, Hlubinová B, Kiňová Sepová H, Pašková Ľ. Impact of culture medium on the interpretation of qRT-PCR data in HepG2 incubated with lactobacilli. Lett Appl Microbiol. 2024 Jun 3;77(6):ovae050. doi: 10.1093/lambio/ovae050. PMID: 38806242.

3

Chrastina M, Poništ S, Tóth J, Czigle S, Pašková Ľ, Vyletelová V, Švík K, Bauerová K. Combination Therapy of Carnosic Acid and Methotrexate Effectively Suppressed the Inflammatory Markers and Oxidative Stress in Experimental Arthritis. Molecules. 2022 Oct 21;27(20):7115. doi: 10.3390/molecules27207115. PMID: 36296709; PMCID: PMC9612293.

4

Pružinská K, Chrastina M, Khademnematolahi S, Vyletelová V, Gajdošová L, Pastvová L, Dráfi F, Poništ S, Pašková Ľ, Kucharská J, Sumbalová Z, Muchová J, Martiniaková S, Bauerová K. Astaxanthin, Compared to Other Carotenoids, Increases the Efficacy of Methotrexate in Rat Adjuvant Arthritis. Int J Mol Sci. 2024 Aug 9;25(16):8710. doi: 10.3390/ijms25168710. PMID: 39201397; PMCID: PMC11354740.

VI.4 - The most significant citations corresponding to the research/artistic/other outputs

1

Hu S, Zhu Y, Zhao X, Li R, Shao G, Gong D, Hu C, Liu H, Xu K, Liu C, Xu M, Zhao Z, Li T, Hu Z, Shao M, Liu J, Li X, Wu H, Li J, Xu Y. Hepatocytic lipocalin-2 controls HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice. Dev Cell. 2023 Nov 6;58(21):2326-2337.e5. doi: 10.1016/j.devcel.2023.09.007. Epub 2023 Oct 19. PMID: 37863040.

2

Al-Kuraishy HM, Hussien NR, Al-Niemi MS, Fahad EH, Al-Buhadily AK, Al-Gareeb AI, Al-Hamash SM, Tsagkaris C, Papadakis M, Alexiou A, Batiha GE. SARS-CoV-2 induced HDL dysfunction may affect the host's response to and recovery from COVID-19. Immun Inflamm Dis. 2023 May;11(5):e861. doi: 10.1002/iid3.861. PMID: 37249296; PMCID: PMC10187021.

3

Azúa-López ZR, Pezzotti MR, González-Díaz Á, Meilhac O, Ureña J, Amaya-Villar R, Castellano A, Varela LM. HDL anti-inflammatory function is impaired and associated with high SAA1 and low APOA4 levels in aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2023 Nov;43(11):1919-1930. doi: 10.1177/0271678X231184806. Epub 2023 Jun 26. PMID: 37357772; PMCID: PMC10676137.

4

Habtemariam S. Anti-Inflammatory Therapeutic Mechanisms of Natural Products: Insight from Rosemary Diterpenes, Carnosic Acid and Carnosol. Biomedicines. 2023 Feb 13;11(2):545. doi: 10.3390/biomedicines11020545. PMID: 36831081; PMCID: PMC9953345.

5

Mitrović J, Hrkač S, Tečer J, Golob M, Ljilja Posavec A, Kolar Mitrović H, Grgurević L. Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis-A Comprehensive Review. Biomedicines. 2023 Apr 24;11(5):1262. doi: 10.3390/biomedicines11051262. PMID: 37238933; PMCID: PMC10216027.

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years

1

VEGA 2/0115/19 New approaches to the treatment of cachexia, inflammation and oxidative stress in experimental arthritis: The effect of various plant extracts of olive leaves, Rhodiola rosea, Tribulus terrestris, and Extra Virgin Olive Oil

The project focused on testing the effectiveness of various natural substances in alleviating the symptoms of inflammation and associated pathologies in a model of adjuvant arthritis in rats. Our contribution involved testing liver samples using the quantitative real-time PCR method, where we monitored changes in various inflammatory, antioxidant, and other genes expression.

active participant (laboratory work)

2

VEGA 1/0429/21: Study of modulation mechanisms of inflammation and lipid metabolism by lactobacilli in the model of nonalcoholic fatty liver disease

The project is focused on studying the mechanisms of action of four Lactobacillus strains (i) on the inflammatory process and lipid metabolism in a liver model (HepG2) and (ii) on the impaired intestinal barrier (Caco-2) under in vitro conditions. In the first phase, we will focus on studying the TLR4 signaling pathway and its downstream molecules, the activation of anti-inflammatory cytokine production, and the stimulation of the expression of negative regulators of the TLR4 signaling pathway in the liver. We will monitor the impact of Lactobacilli on the regulation of lipid metabolism (influx, efflux, synthesis, and degradation of cholesterol, triacylglycerols, and fatty acids). In the second phase, we will optimize the inflammatory co-culture model of enterocytes (Caco-2) with hepatocytes (HepG2). At the molecular level, we will analyze the ability of Lactobacilli to restore the impaired permeability of the Caco-2 monolayer and influence the inflammatory process and lipid metabolism in the model of inter-organ communication over time. We aim to contribute to elucidating the mechanisms underlying NAFLD development and the possibilities of its modulation by probiotics with our findings.

active participant (laboratory work)

https://www.fpharm.uniba.sk/pracoviska/katedra-bunkovej-a-molekularnej-biologie-lieciv/vedecko-vyskumna-cinnost/grantove-projekty/vega-1042921/

3

Grant UK/162/2023 Creation, analysis, and optimization of an in vitro model in a human HepG2 hepatocyte cell culture for studying inflammation-induced changes in hepatic mRNA expression of genes related to HDL.

The project was focused on the creation and optimization of an in vitro model in HepG2 cells using THP-1 monocyte-conditioned medium (CM). Due to its high content of proinflammatory cytokines and mediators, CM appears to be a suitable agent for inducing inflammation-driven changes in lipid metabolism in hepatocytes, as confirmed by mRNA expression changes in HepG2 cells exposed to CM.

principal investigator

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

Membership in COST Action CA21153 - European Network for Collaboration in the Field of Atherosclerosis. Active participation in two events of this project:

3rd MC/WG meeting of COST Action AtheroNET CA21153 in Valencia - poster presentation
Training school: Omics for precision Medicine in ASCVD in Crete

Date of last update

2025-01-23